Influence of the introduction of an electronic diabetes management system in patients with type 2 diabetes mellitus on a medical ward.
- Conditions
- E11Type 2 diabetes mellitus
- Registration Number
- DRKS00016983
- Lead Sponsor
- Medizinische Universität Graz Klinik für Innere Medizin Abteilung für Endokrinologie & Diabetologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
•Type 2 diabetes mellitus or recent / diagnosed hyperglycaemia
• Age> 18 years
• treatment with free therapy
Exclusion Criteria
•Type 1 diabetes mellitus, pancreoprive diabetes, gestational diabetes
• Pregnancy
• Continuous parenteral nutrition
• IV insulin therapy
• Treatment with the decision support component of GlucoTab®
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mean daily blood glucose level
- Secondary Outcome Measures
Name Time Method • Number of daily blood glucose measurements<br>• Oral antidiabetics<br>• Insulin doses (basal insulin, bolus insulin, mixed insulin, daily insulin, and correction insulin dose)<br>• Midprandial (morning, noon, evening) and bedtime blood glucose<br>• hypoglycaemia (<40mg / dl, <60mg / dl, <70mg / dl)<br>• hyperglycaemia (> 180mg / dl,> 200mg / dl,> 300mg / dl)<br>• concomitant medication that influences the glucose metabolism (eg cortisone)<br>• Number of patients receiving free therapy (paper-based or GlucoTab®-based) vs. Decision Support Therapy according to GucoTab®<br>• Blood glucose control comparison with GlucoTab® decision support vs. free therapy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does an electronic diabetes management system impact glycemic control in T2DM patients compared to standard care protocols?
What biomarkers correlate with improved outcomes in T2DM patients using electronic glucose monitoring systems?
What are the potential adverse events associated with electronic diabetes management systems in hospitalized T2DM patients?
How does the integration of electronic diabetes systems affect medication adherence and hypoglycemic episodes in T2DM?
What role do SGLT2 inhibitors or GLP-1 agonists play in conjunction with electronic diabetes management systems for T2DM?